LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

496.23 -0.98

Buy Sell

Overview

Share price change

24h

Current

Min

488.04

Max

502.6

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+33.92% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	1.4B 12B
Previous open	497.21
Previous close	496.23

News Sentiment

By Acuity

40%

60%

134 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 maj 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 maj 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 maj 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 maj 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 maj 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 maj 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 maj 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 maj 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 maj 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 maj 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 maj 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 maj 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 maj 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 maj 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 maj 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 maj 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 maj 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 maj 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

33.92% upside

12 Months Forecast

Average 665.63 USD 33.92%

High 964 USD

Low 550 USD

Based on 8 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

134 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.